Utilizing LEADtm RNAi Technology to Treat Obesity and Metabolic Disease
- Novel ligand-mediated approaches for selectively targeting adipocytes, muscle, and other metabolic compartments are needed to realize the potential of RNAi for obesity therapy
- LEADTM technology is a new ligand-and-enhancer conjugation approach that enables improved specificity and potency for obesity targets across multiple biological mechanisms
- In this presentation, we will share clinical and preclinical data demonstrating the potential for best-in-class RNAi payloads, differentiated pharmaceutical properties, and therapeutic proof-of-concept to treat obesity and metabolic disorders